These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9102661)

  • 1. [Antiviral agents that act in the early phases of the viral cycle].
    Damonte EB
    Rev Argent Microbiol; 1996; 28(4):204-16. PubMed ID: 9102661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle.
    De Clercq E
    Biomed Pharmacother; 1996; 50(5):207-15. PubMed ID: 8949401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives for the chemotherapy and chemoprophylaxis of AIDS (acquired immune deficiency syndrome).
    De Clercq E
    Verh K Acad Geneeskd Belg; 1992; 54(1):57-88; discussion 88-9. PubMed ID: 1636322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs.
    Witvrouw M; De Clercq E
    Gen Pharmacol; 1997 Oct; 29(4):497-511. PubMed ID: 9352294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives for the chemotherapy of AIDS.
    De Clercq E
    Anticancer Res; 1987; 7(5B):1023-38. PubMed ID: 3324934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
    Nijhuis M; van Maarseveen NM; Boucher CA
    Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple model to predict the effectiveness of molecules that block attachment of human rhinoviruses and other viruses.
    Wickham TJ; Shuler ML; Hammer DA
    Biotechnol Prog; 1995; 11(2):164-70. PubMed ID: 7766100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions.
    Bertaux C; Daelemans D; Meertens L; Cormier EG; Reinus JF; Peumans WJ; Van Damme EJ; Igarashi Y; Oki T; Schols D; Dragic T; Balzarini J
    Virology; 2007 Sep; 366(1):40-50. PubMed ID: 17498767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms.
    Korth MJ; Taylor MD; Katze MG
    Virology; 1998 Aug; 247(2):265-73. PubMed ID: 9705919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyanion inhibitors of HIV and other viruses. 7. Polyanionic compounds and polyzwitterionic compounds derived from cyclodextrins as inhibitors of HIV transmission.
    Leydet A; Moullet C; Roque JP; Witvrouw M; Pannecouque C; Andrei G; Snoeck R; Neyts J; Schols D; De Clercq E
    J Med Chem; 1998 Dec; 41(25):4927-32. PubMed ID: 9836609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides.
    Rusnati M; Vicenzi E; Donalisio M; Oreste P; Landolfo S; Lembo D
    Pharmacol Ther; 2009 Sep; 123(3):310-22. PubMed ID: 19447134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
    Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
    Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV.
    Parris GE
    Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral chemotherapy: mechanisms of action, evaluation of activity, resistance and future developments].
    Agut H; Fillet AM; Huraux JM
    Pathol Biol (Paris); 1993 Oct; 41(8 Pt 2):770-6. PubMed ID: 8309719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.